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CONSTRUCTION OF VAC IV: TOWARDS THE DEVELOPMENT OF DNA VACCINE 
 CANDIDATE AGAINST TUBERCULOSIS 
 
ABSTRACT 
 
Tuberculosis (TB) is the one of leading cause of death in the world, caused by a 
bacterium, Mycobacterium tuberculosis. The disease affects 1.7 billion people every year 
which is equivalent to one-third of the entire world population. The recent increase in the 
incidence of TB, particularly antibiotic-resistant TB underscores the need for an effective 
vaccine against this important disease. The only vaccine currently in use is the live, 
attenuated strain of Mycobacterium bovis, bacille Calmette-Guérin (BCG) that was 
produced in the early 1920s. In this study, a plasmid DNA encoding Mtb8.4, 30kDa 
(Ag85B) and 32kDa (Ag85A) genes of M. tuberculosis was constructed as an alternative 
vaccine candidate against TB. Using assembly polymerase chain reaction (PCR) method, 
the synthetic gene, designated as VacIV gene was constructed from overlapping 
oligonucleotides of the desired genes. The VacIV gene was successfully cloned into an 
eukaryotic expression vector, pVAX1© to produce a DNA vaccine candidate namely 
pVaxVacIV. The VacIV gene also was successfully expressed in E. coli expression 
system. The immunogenicity of this vaccine candidate was then tested in mice. Mice were 
immunized intramuscularly with the vaccine candidate. Control mice were immunized with 
the blank vector (pVAX1©). The splenocytes were cultured with antigens such as purified 
protein derivatives (PPD), rVacIV protein and Mtb8.4 synthetic peptide for lymphocytes 
transformation test (LTT) and cytokines assay. Sera were also collected to determine the 
level of serum IgG subclasses. Our results showed that lymphocytes from mice immunized 
with the pVaxVacIV secreted a higher gamma interferon (IFN-γ) but not the interleukin-4 
(IL-4) levels compared to the lymphocytes from the control mice. Mice immunized with 
 xv
pVaxVacIV also showed high lymphocytes stimulation index and high ratio of IgG2a:IgG1 
as compared to control group. These results showed that the newly constructed DNA 
vaccine candidate, pVaxVacIV was immunogenic in mice and can be further developed as 
a potential vaccine candidate for TB. 
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PEMBINAAN VAC IV: KE ARAH PEMBANGUNAN CALON VAKSIN DNA TERHADAP 
PENYAKIT TUBERKULOSIS 
 
ABSTRAK 
 
Tuberkulosis (TB) merupakan salah satu punca kematian di dunia ini, disebabkan oleh 
bakteria Mycobacterium tuberculosis. Penyakit ini telah menyerang 1.7 billion penduduk 
dunia setiap tahun, bersamaan dengan satu per tiga daripada keseluruhan jumlah 
popoulasi di dunia. Disebabkan peningkatan jumlah kes TB pada masa kini, terutamanya 
TB rintang antibiotik, maka vaksin yang lebih efektif adalah diperlukan bagi melawan 
penyakit ini. Satu-satunya vaksin yang digunakan sekarang adalah vaksin strain 
teratenuat, Mycobacterium bovis, bacille Calmette-Guerin (BCG) yang telah dibangunkan 
sejak tahun 1920-an. Dalam penyelidikan ini, plasmid DNA yang mengekodkan gen 
Mtb8.4, 30kDa (Ag85B) dan 32kDa (Ag85A) dari M. tuberculosis telah dibangunkan 
sebagai vaksin alternatif terhadap TB. Dengan menggunakan teknik tindakbalas 
polymerase berantai (PCR), gen sintetik yang dikenali sebagai VacIV telah dibina daripada 
oligonukleotida-oligonukleotida yang mengekodkan gen yang dikehendaki. Gen VacIV 
juga telah berjaya diklonkan ke dalam vektor pengekspresian eukariotik iaitu pVAX1, bagi 
menghasilkan calon vaksin yang diberi nama pVaxVacIV. Gene VacIV telah berjaya 
diekspreskan dalam sistem pengekspresan E. coli. Kajian imunogenisiti terhadap calon 
vaksin ini telah dilakukan ke atas mencit. Mencit telah diimunisasikan melalui kaedah 
intramuskular (intra-otot) dengan calon vaksin tersebut manakala mencit kawalan 
diimunisasikan dengan vektor tanpa gen VacIV  (pVAX1). Sel limfosit telah dikulturkan 
dengan antigen-antigen iaitu ‘purified protein derivatives’ (PPD), protein rekombinan VacIV 
dan peptida sintetik Mtb8.4 untuk ujian transformasi limfosit (LTT) dan penentuan asai 
sitokin. Serum mencit telah dikumpul untuk menentukan aras sub-kelas IgG. Hasil kajian 
 xvii
kami telah menunjukkan bahawa mencit yang diimunisasikan dengan pVaxVacIV 
merembeskan interferon gamma (IFN-γ) lebih tinggi tetapi tidak interleukin-4 (IL-4) 
berbanding mencit kawalan. Mencit yang diimunisasikan dengan pVaxVacIV juga 
menunjukkan indeks stimulasi limfosit dan nisbah IgG2a terhadap IgG1 yang tinggi 
berbanding mencit kawalan. Keputusan ini menunjukkan bahawa calon vaksin DNA yang 
baru ini adalah imunogenik terhadap mencit boleh dibangunkan sebagai calon vaksin yang 
berpotensi untuk mencegah TB. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1                   Background of Tuberculosis 
 
1.1.1 Overview of TB 
 
Tuberculosis (TB) is among the most frequent infectious disease nowadays. In 1882, 
Robert Koch had identified the responsible causative agent of this disease which is the 
tubercle bacillus, Mycobacterium tuberculosis (Kanai, 1990). M. tuberculosis infects about 
one-third of the world’s population, causing approximately 3 million deaths annually (Dye 
et al., 1999). In 1993, WHO declared the current TB epidemic ‘a global emergency’ as it 
became a major cause of death in the developing world (WHO, 1994). Until now, TB 
remains a major global health threat and almost 200 millions people are currently infected 
with M. tuberculosis, resulting in 50,000 new cases of disease every year (WHO, 2005, 
Kaufmann, 2005).  
 
TB is accountable for the deaths of an additional 900,000 people with Acquired 
Immunodeficiency Syndrome (AIDS) annually (Dye et al., 1999; Kochi, 1991). Co-infection 
with human immunodeficiency virus (HIV) is the most important risk for the development of 
latent M. tuberculosis infection (Ibanga et al., 2006). In addition, the problem is 
compounded by the global emergence of M. tuberculosis strains which are resistant to the 
major antibiotics used to treat TB (Lauzardo & Ashkin, 2000).  
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1.1.2 History of TB 
 
The existent of M. tuberculosis was realized since 2400 B.C through the fragments of the 
spinal column from Egyptian mummies, which showed definite signs of TB. The term 
“phthisis”, consumption, appears first in Greek literature. Around 460 B.C, Hippocrates 
identified phthisis as the most common disease of the times, and notable that it was almost 
fatal. Due to common phthisis-related fatalities, he warned his colleagues to beware of TB 
patients in late stages of the disease, because their expected deaths might damage the 
reputations of the attending physicians (Kanai, 1990). 
 
TB was present many centuries before Robert Koch first isolated the tubercle bacillus in 
1882 (Kanai, 1990). Koch’s discovery has lead to the detection of the tubercle bacilli in 
variety methods such as microscopy, animal inoculation and by an in vitro culture. Koch’s 
finding was the starting point for the development of scientific research of TB, both 
practical and theoretical. 
 
Clinically, there are  variety of types of TB such as bone TB, lymph node TB, pleural TB, 
genitourinary TB, central nervous system (tuberculomeningitis) tuberculosis, abdominal 
TB, pericardial TB and pulmonary TB (Kumar et al., 2003). Among all of these, pulmonary 
TB is the most common and is responsible for the most death per year (Butler, 2000). The 
disease remained a bane for many years as there is no effective treatment available 
(Goodfellow & Magee, 1998).  
 
In 1908, a bacteriologist from France Pasteur Institute named Calmette, together with his 
friend Guerin had succeeded to produce a vaccine against TB from a live-attenuated M. 
bovis. This vaccine is known as bacille Calmette-Guerin (BCG) and practically used in 
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human since 1921. The development of this vaccine also led to the production of 
antituberculous drugs such as isoniazid (INH), kanamycin (KM), pyrazinamide (PZA), 
ethambutol (EB) and rifampicin (RFP)  (Kanai, 1990). 
 
1.1.3 Epidemiology of TB in Malaysia 
 
The number of TB notification had increased for over 10 years. In Malaysia, the incidence 
rate per 100,000 populations is 64.7. The incidence of smear positive cases is 34.7 per 
100,000 populations. The state with the highest disease burden is Sabah, followed by 
Wilayah Persekutuan, Sarawak and Pulau Pinang respectively. In the meantime, the 
majority of cases are in the 15 to 54 years age group (67.7 %) followed by above 55 years 
age group (29.5 %) and children below 14 years age group (2.8 %) respectively  
(Kuppusamy, 2004) 
 
The increase number of TB notification is associated with co-infection with HIV infection. 
Since most patients with TB/HIV co-infection are seen with advanced TB in Malaysia, the 
number of deaths due to TB/HIV has also increased. Moreover, the existence of immigrant 
population contributes to increase the number of TB cases. About 10 % of TB cases 
notified in Malaysia are discovered among the immigrant population, particularly the 
immigrant workers from high TB burden neighbouring countries such as Philippines, 
Indonesia, Thailand, Burmese and Bangladesh. Among the variety types of TB, pulmonary 
TB represents 91 % of the total cases. The most common type of TB in Malaysia are TB 
lymphadenitis, bone and joint TB and miliary TB (Kuppusamy, 2004). 
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1.1.4 M.  tuberculosis 
 
Mycobacteria is a gram-positive (no outer cell membrane), belongs to the family of 
Actinomyces. Most mycobacteria are found in habitats such as water or soil. However, a 
few are intracellular pathogens which infect animals and humans. M. tuberculosis, along 
with M. bovis, M. africanum and M. microti are the causative agents of TB and are 
members of the M. tuberculosis complex species. Each member of the TB complexes are 
pathogenic, but M. tuberculosis is the most pathogenic for humans while M. bovis usually 
infects animals (online at http://www-micro.msb.le.ac.uk/Video/Mtuberculosis.html ) 
 
M. tuberculosis is a non-motile rod-shaped bacterium. The rods are 2-4 um in length and 
0.2-0.5 um in width. M. tuberculosis is an obligate aerobe, so it can grow most successfully 
in tissues with high oxygen content, such as the lungs. A Mycobacterium is a facultative 
intracellular parasite, usually of macrophages, and has a slow generation time, 15-20 
hours, a physiological features that may supply to its virulence. Mycobacterium species are 
classified as acid-fast bacteria due to their impermeability by certain dyes and stains. Once 
stained, acid-fast bacteria will retain dyes when heated and treated with acidified organic 
compounds. One acid-fast staining method for M. tuberculosis is the Ziehl-Neelsen 
staining. When this method is used, the M. tuberculosis smear is fixed, stained with carbol-
fuchsin (a pink dye) and decolorized with acid-alcohol. The smear is counterstained with 
methylene-blue or certain other dyes. Acid-fast bacilli appear pink in a contrasting 
background (Todar, 2005). The genome of M. tuberculosis consists of a single circular 
chromosome with 4.4 mega base pair and G+C contents approximately 65.6 % (Cole et 
al., 1998). 
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The cell wall structure of M. tuberculosis earns special consideration because it is unique 
among prokaryotes and is a major determinant of virulence for the bacterium. The cell wall 
complex contains peptidoglycan and complex lipids (Bloom, 1994). Over 60% of the 
mycobacterial cell wall is lipid. The lipid fraction of M. tuberculosis cell wall consists of 
three major components. They are mycolic acid, cord factor and wax-D (Kanai, 1990). 
Mycolic acids are unique alpha-branched lipids found in the cell walls of Mycobacterium 
and Corynebacterium. The composition is 50% of the dry weight of the mycobacterial cell 
envelope.  Mycolic acids are strong hydrophobic molecules that form a lipid shell around 
the organism and affect the permeability properties at the cell surface.  Mycolic acids are 
considered to be a significant determinant of virulence in M. tuberculosis. Most likely, they 
prevent attack of the mycobacteria by cationic proteins, lysozyme and oxygen radicals in 
the phagocytic granule. They also protect extracellular mycobacteria from complement 
deposition in serum (Todar, 2005). 
The high concentration of lipid in the cell wall of M. tuberculosis has been associated with 
these properties of the bacterium including impermeability to stains and dyes, resistance to 
many antibiotics, resistance to kill by acidic and alkaline compounds, resistance to osmotic 
lysis via complement deposition and resistance to lethal oxidations and survival inside the 
macrophages. 
Meanwhile, cord factor is toxic to mammalian cells and most abundantly produced in 
virulent strains of M. tuberculosis. Wax-D in the cell envelope is the major component of 
Freund's complete adjuvant (CFA), which is responsible in the impermeability of the 
mycobacterial cell wall (Todar, 2005). 
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1.1.5 Pathogenesis of TB 
Tuberculosis is commonly acquired by inhalation of the tubercle bacilli through talking, 
coughing and sneezing. Most of the healthy people will beat a potential infection with 
activated microphages, especially when the dose is low. Disease progression depends on 
strain of M. tuberculosis, prior exposure, infectious dose and the immune status of the host 
(Tortora et al. 1997; Todar, 2005). 
The pathogenesis of TB start once after droplet nuclei are inhaled, the bacteria are 
nonspecifically taken up by alveolar macrophages. However, the macrophages are not 
activated and are unable to destroy the intracellular organisms. TB begins when droplet 
nuclei reach the alveoli. The smaller droplet nuclei may reach the small air sacs of the lung 
(the alveoli), where infection begins. The second stage begins 7-21 days after initial 
infection. M. tuberculosis multiplies within normal macrophages until the macrophages 
burst. Other macrophages are released from peripheral blood. These macrophages also 
phagocytose M. tuberculosis but they are also unactivated and cannot destroy M. 
tuberculosis. Macrophages and other defensive cells accumulate at the infection site, 
forming a surrounding layer, walled-off lesion called a tubercle (means lump or knob) 
(Tortora et al. 1997; Todar, 2005). 
The third stage begins after several weeks. Many of the macrophages die, releasing 
tubercle bacilli. The interior of tubercle becomes caseous (cheeselike in consistency). M. 
tuberculosis cannot multiply within these tubercles because of the low pH and anoxic 
environment. The disease may become dormant after this stage and M. tuberculosis 
persist within these tubercles for extended periods (Tortora et al. 1997; Todar, 2005). 
At the fourth stage, a caseous lesion is slowly enlarged and become less cheeselike and 
more liquid, which called liquefaction. Although many activated macrophages can be found 
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surrounding the tubercles, many other macrophages present remain unactivated or poorly 
activated. M. tuberculosis uses these macrophages to replicate and hence the tubercle 
grows. The growing tubercle may attack a bronchus. Thus, M. tuberculosis infection can 
spread to other parts of the lung. The tubercle may invade an artery or other blood supply 
line. The hematogenous spread of M. tuberculosis may result in an extrapulmonary TB 
otherwise known as milliary tuberculosis (Tortora et al. 1997; Todar, 2005). 
At the fifth stage, the disease now becomes very infectious. The liquid makes for an 
efficient aerosol droplets when coughed up and bacteria begin to escape the tubercle. 
These microorganisms begin to enter the airways of the lung, and then the circulatory and 
lymphatic systems (Tortora et al. 1997; Todar, 2005). 
The symptoms that often occur in TB patient are fever, night-time sweating, loss of weight, 
persistent cough (often bringing up blood), constant tiredness and loss of appetite (Tortora 
et al., 1997; Todar, 2005). 
1.1.6             Diagnosis of TB 
 
In order to identify and diagnose M. tuberculosis infection, several ways can be used such 
as bacteriological or by immunological methods (Kanai, 1990). M. tuberculosis can be 
detected in sputum sample from patient by microscopic examination using Ziehl-Neelsen 
staining method. This method is performed to detect acid-fast bacilli in sputum. Ziehl-
Neelsen staining method is less expensive and can detect the mycobacteria easily and 
quickly (Cambiaso et al., 1990; Kanai, 1990). Ziehl-Neelsen staining method is 
recommended by the International Union against TB and Lung Disease (IUATLD) and 
WHO (Todar, 2005).  
 
 8
Other method used to make a diagnosis of TB is sample culturing. The culturing method 
commonly used is the BACTEC System. The media used in the BACTEC system contains 
radio-labeled palmitate as the sole carbon source. As M. tuberculosis multiplies, it breaks 
down the palmitate and liberates radio-labeled CO2. M. tuberculosis growth can be 
detected in 9-16 days through the BACTEC system, in contrast of using conventional 
media which takes 4-6 weeks (Chien et al., 2000; Todar, 2005). 
 
More recently, a polymerase chain reaction (PCR) assay was used for the rapid detection 
of M. tuberculosis in sputum samples. The most commonly target DNA is a 123 bp 
segment of IS6110, which is repeated in the M. tuberculosis chromosome and is specific 
for the M. tuberculosis complex. The PCR assay involves several steps which include lyse 
the mycobacteria, extraction the DNA, and amplification the 123-bp target DNA. This 
assay provides a sensitive and specific means for the laboratory diagnosis of TB within 48 
hour that is relatively simple to perform (Eisenach et al., 1991). One of the TB detection 
kits currently available in this country is EZ TB Amp PCR Detection Kit (MBDr, Malaysia). 
Due to the high sensitivity and short time needed to detect the presence of the bacteria in 
a clinical sample, this kit can help rapidly identify TB patients and thus help to slow down 
the spread of the disease (online at: http://www.informm.usm.my/index.php?option=com_ 
content&task=view&id=88&Itemid=126). 
 
TB infection also can be detected using immunological approach such as tuberculin skin 
test. This particular in vivo test is commonly used for identifying latent infection of M. 
tuberculosis. Using protein purified derivatives (PPD) as a tuberculin, PPD is administered 
intracutaneously to the subject. If the injected person has been infected with TB in the 
past, sensitisized T cells react against this protein and produce a delay hypersensitivity 
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reaction within 48 hours. This reaction appears as a reddening of the area around the 
injected site (Tortora et al., 1997; Lee & Holzman, 2002; Frieden et al., 2003). 
 
1.2                Immunity to TB 
 
Immunity against M. tuberculosis infection is closely related with innate and adaptive 
immunity. Primary cell such as dendritic cell and macrophages are involved in the innate 
immunity and play an essential role in the initiation of the adaptive immunity. Both humoral 
and cell-mediated immune responses are elicited by M. tuberculosis infection (Laal et al., 
1997). 
 
Humoral responses in TB have been studied for several decades, primarily for the purpose 
of developing serodiagnostic assays (Laal et al., 1997).  It is acknowledged that TB 
patients produce antibodies to more than one proteinaceous antigen. The humoral 
responses exist in TB patients, depending upon the disease stage, the patient's 
immunological background, the antituberculous therapy, and/or the differential gene 
expression of different strains of M. tuberculosis (Julian et al., 2004).  
 
Cellular-mediated immune response is the major protective immune response more 
eagerly than humoral responses (Kaufmann, 1995; Feng et al., 1999). Macrophages and 
T-lymphocytes are important properties in cellular mediated immunity. Exclusion of M. 
tuberculosis infection mainly depends on the success of the interaction between infected 
macrophages and T lymphocytes. Acquired immunodeficiencies, especially HIV infection, 
have significantly shown the importance of cellular immunity in TB. CD4+ T-cell affect their 
protective effect by the production of cytokines, mainly gamma interferon (IFN-γ) after 
stimulation with mycobacterial antigens. CD8+ T cells are other T cell subset, which 
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contribute as well, by secreting cytokines and lysing infected cells (Stenger & Modlin, 
1999; Geluk et al., 2000). 
 
Macrophages are the major component in immune system and play a multiplicity of roles in 
M. tuberculosis infection. The organism can grow inside resting macrophages but can be 
inhibited or killed when the macrophage is activated (Flynn, 2004). The role of 
macrophages including antigen processing and presentation and effector cell functions 
(Adams & Hamilton, 1992). The interaction between infected macrophages or dendritic 
cells and T lymphocytes is a main key in elimination of M. tuberculosis infection. 
Mycobacterial antigens presentation by macrophages and dendritic cells elicit T-cells 
response in the context of major histocompatibility complex (MHC). MHC molecules 
include class I and class II for the presentation of mycobacterial antigens (Flynn, 2004). 
After processing mycobacterial antigen in phagolysosomal compartments of professional 
antigen-presenting cells (APC), MHC class II molecules present these mycobacterial 
proteins to antigen specific CD4+T-cells. In contrast with MHC class II, MHC class I 
molecules present mycobacterial proteins to antigen-specific CD8+T-cells, which then lead 
to the terminating of infected cells upon peptide-MHC recognition through cytolytic function 
of cytotoxic T-lymphocytes (CTL) by releasing cytotoxic molecules, perforin which induce 
apoptosis in infected cells (Esser et al., 2003). 
 
The major cell population in cell-mediated immunity in TB is the CD4+ T-lymphocytes. 
CD4+ T-cell express the α/ß T-cell receptor, and they involved in recognition of antigens 
that has been processed in phagosomes and presented as small fragment in the context 
of MHC class II molecules  on the surface of antigen presenting cell such as macrophages 
or dendritic cells. CD4+ T-cells help to amplify the host immune response by activating 
effector cells and taking on other immune cells of the site of disease (Berman et al., 1996; 
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Boom, 1996). Many studies of animal models of TB have suggested that both CD4+ and 
CD8+ T-cells have a protective role in M. tuberculosis infection (Flynn et al., 1995; Coler et 
al., 2001). Within one week of infection with virulent M. tuberculosis, the number of 
activated CD4+ and CD8+T-cells in the lung-draining lymph nodes had increased. This 
finding indicated that activated T-cells had migrated to the site of infection and had 
interacted with APC (Serbina et al., 2000). 
 
CD4+ T-cells can be divided into two subsets of effector CD4+ T-lymphocytes, called T 
helper type 1 (Th1) and type 2 (Th2) respectively, which were characterized by their 
cytokines production.  Th1 cells were characterized by the production of interferon gamma 
(IFN-γ), tumor necrosis factor-α (TNF-α) and IL-2, whereas Th2 cells produce cytokines 
such as IL-4, IL-5 and IL-10 (Barnes, 1993). Immunity to M. tuberculosis is dependent on 
the generation of Th1 type cellular immune response. Th1 type cytokine seem to be 
essential for protective immunity against TB. IFN-γ is the key activating agents that triggers 
the antimycobacterial effects (Rook et al., 1986; Flesch & Kaufmann, 1990). IFN-γ play an 
important role to activate macrophages, followed by killing the mycobacterial during 
phagocytosis. Bacteria that are not killed by this process have their multiplication inhibited 
inside IFN-γ activated macrophages. An additional function is then handed out by cytotoxic 
CD8+ T cells which release intracellular bacteria from infected cell, so that they can be 
killed during phagocytosis by activated macrophages (De Lebiro et al., 1988). 
 
IL-12 production may be an important regulator of T-cell phenotypes in TB and as a crucial 
cytokines in controlling M. tuberculosis infection. Flynn and collegues (1995) showed that 
the exogenous administration of IL-12 into BALB/c mice can improve survival from M. 
tuberculosis infection. Zhang et al., 1994 has demonstrated that cytokines production in 
pleural fluid from patients with tuberculosis pleurisy and found high level of IL-12 after 
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stimulation of pleural fluid cells with M. tuberculosis. Human with recessive mutation in IL-
12p40 are more susceptible to mycobacterial infection (Ottenhof et al., 1998). IL-12 is 
known to induce a Th1-type response in undifferentiated CD4+ cells (Lin et al., 1996). IL-12 
is induced subsequent phagocytosis of M. tuberculosis bacilli by macrophages and 
dendritic cells which drives enlargement of a Th1 response with the production of IFN-γ. 
 
IFN-γ, which is the major macrophages activating cytokines and other Th1 cytokines are 
essential as stated previously. It is already demonstrated that T-cells function in direct 
killing of mycobacterial and lyse infected macrophages. Macrophage lysis appears to be 
the qualification for killing by T-cells of microbes living inside macrophages. Furthermore, 
lysis of infected macrophages could promote release of mycobacteria from inability 
macrophages to other competent monocytes (Silva et al., 2001). 
 
1.3          TB vaccine development 
 
1.3.1  Failure in BCG vaccination 
 
Bacille Calmette-Guerin (BCG) vaccine is an attenuated strain of M. bovis applied in 1921 
in France by Albert Calmette and Camille Guerin as a vaccine against TB. The mechanism 
of protection from BCG vaccination involves a reduction of the haematogenous spread of 
bacilli from the site of primary infection. It also protects against acute symptom of the 
disease and reduces a lifelong risk of endogenous reactivation and propagation from prior 
infection (Luelmo, 1982; Arbelaez et al., 2000). 
 
The efficacy of BCG vaccination, however, has been strongly issued. Multiple studies have 
been conducted to evaluate BCG vaccine efficacy as a preventive measure against TB. 
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Although vaccination with BCG is widely practiced worldwide, the efficacy is ranging from 0 
% to 85 %, among different clinical trials and geographically distinct populations. Baily 
(1980) has demonstrated through his study that BCG vaccine was found to offer no 
protection to individual over the age of 12-years among Tamil Nadu population in South 
India. A current review of all previous controlled clinical trials concluded that vaccination 
with BCG reduced the overall risk of tuberculosis by approximately 50 % (Colditz et al., 
1994).  
 
The reasons for the different effect of BCG vaccination are subjected to differences of 
substrains of the vaccine used in different trials and also due to differences dose and 
vaccination schedules. The difference substrains used including Glaxo, Danish, Paris, 
Montreal, Phipps, Tice, Birkhaug and Madras (Chan & Kaufmann, 1994). Furthermore, 
genetics differences in human population also contribute to the efficacy of BCG 
vaccination. Genetic factors are important in determining the host susceptibility to infection 
against mycobacteria (Bellamy & Hill, 1998). 
 
In addition, BCG is less effective at preventing late reactivation and pulmonary TB, thus, 
BCG vaccination has not contributed to control the spread of TB (Kristensen et al., 2000). 
Furthermore, the effectiveness of early BCG vaccination in preventing TB among adult 
could be modified by the presence of HIV infection. The immunosuppression produced by 
HIV infection could alter the response to vaccine and increase the risk of mycobacterial 
infection (Arbelaez et al., 2000). 
 
Due to the less effectiveness of BCG vaccination, there is an urgent need to develop a 
better or improved TB vaccine as an alternative to BCG.  
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1.3.2            Features of an ideal vaccine 
 
In order to develop an ideal vaccine candidate in preventing TB infection, there are some 
characteristics that should be considered. The vaccine candidate should be safe to be 
used in newborns, adults and immunosuppressed person (including the HIV-infected 
person). An ideal vaccines should have an ability to induce both humoral and cellular 
immune response in newborns and adults, provide long lasting immunity, immunogenic in 
HIV infection, protective against primary disease including pulmonary and meningeal TB, 
effective against reactivation disease, useful in person with previous BCG immunization 
and definitely low cost, easy to manufacture and administer (von Reyn & Vuola, 2002; 
McShane, 2004). 
 
1.3.3           New approaches in TB vaccine development 
 
Several approaches have been used in the development of TB vaccine, including DNA 
vaccination, subunit vaccine, recombinant BCG and recombinant microbial vaccine. 
 
1.3.3.1      Subunit vaccine  
 
Since the current whole cell vaccine for TB did not show hopeful result, researchers are 
now targeting individual protein fraction of the BCG or M. tuberculosis either alone or in 
combination to boost the immune system (Kumar et al., 2003). The advantages of subunit 
vaccine delivered as protein or DNA or non-replicating viral vector include their safety 
profile and the lack of tissue damage or scarring (Britton & Palendira, 2003). Subunit 
vaccine is considered as a booster on top of a BCG vaccination. These subunit vaccine 
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candidates therefore need to perform better only when given as a booster after BCG 
priming (Baumann et al., 2006). 
 
1.3.3.2       DNA vaccine 
 
DNA vaccination is an effortless method to generate both humoral and cellular immune 
responses. DNA vaccine can stimulate both exogenous (MHC-class II restricted) and 
endogenous (MHC-class I restricted) antigens presentation pathways (Huygen, 2003). 
Both antibodies and cell-mediated immune responses have been induced by direct 
intramuscular inoculation with plasmid DNA encoding viral proteins. These responses have 
been found to be protective in various animal models of viral diseases. Immunization by 
direct transfection in vivo with plasmid DNA will elicit CD8+ cytotoxic T lymphocytes (CTL). 
These CTL recognize peptides 9-11 amino acids in length bound to Class I molecules of 
the MHC. Therefore, protein antigens produced by DNA vaccination put on access to 
pathways of antigen presentation via Class I MHC molecules, a system of antigen 
presentation that is most frequently utilize by live attenuated virus vaccines, recombinant 
viral vectors, and intracellular bacteria such as Listeria or Shigella (Donnelly et al., 1997).  
 
The mechanism of action of plasmid DNA vaccine is illustrated in Figure 1.1. DNA vaccine 
is constructed by inserting the most promising antigens under strong promoters in an 
expression vector. Then, the DNA vaccine is administered via intramuscularly route. This 
technique involves the preparation of pure DNA which is less expensive than pure protein, 
make it very cost effective and appealing.  
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Figure 1.1: Mechanism of action of plasmid DNA vaccines. (1) DNA uptake by cells can 
be facile (for naked DNA) or facilitated (using delivery vehicles). (2) When expressed by 
antigen presenting cells (APCs), the antigens can be processed and presented by major 
histocompatibility complex (MHC) molecules directly to naive T cells (direct priming).  
(3)Alternatively, the antigens that are released from transfected cells (e.g. by apoptosis) 
can be internalized by ‘bystander’ APCs such as dendritic cells (DCs) for presentation by 
MHC molecules (cross priming)(adapted from Ulmer et al., 2006). 
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DNA vaccine candidates expressing selected M. tuberculosis epitopes have been tested in 
animal models and have shown to be immunogenic and also provide some protection 
against infection (Huygen et al., 1996; Kamath et al., 1999; Lowrie et al.,1999). 
 
1.3.3.3       Recombinant BCG 
 
Recombinant BCG (rBCG) is one of approaches in vaccine development strategies. The 
advantages of using BCG as a platform for new TB vaccine are the low cost, safe and 
widespreadly used (Huebner, 1996). The genes encoding immunodominant antigens have 
been inserted into BCG to increase its efficacy. Recent studies have demonstrated that 
rBCG expressing protective viral or bacterial antigens may induce strong cellular immune 
response and under some condition good antibody responses (Dhar et al., 2000). Recent 
study by Rapeah and Norazmi (2006) had shown recombinant BCG expressing the 
malarial epitopes F2R(II)EBA and (NANP)3 as well as two T cell epitopes of the M. 
tuberculosis ESAT-6 antigen, elicited specific immune response against these epitopes. 
Flow cytometric analyses showed elevated numbers of CD4+ lymphocytes expressing IFN-
γ and IL-2 against the ESAT-6 peptides, suggesting a specific Th1-mediated response. 
Currently, another advanced candidate has been developed, so called rBCG∆ureC:hly, 
which express the listeriolysin molecule (Hly) of Listeria monocytogenes has increased the 
immunogenecity of this vaccine (Grode et al., 2005). 
 
1.3.3.4     Recombinant microbial vaccine 
 
Recombinant modified vaccinia virus Ankara (MVA) is an example of recombinant 
microbial vaccine. MVA is an attenuated strain of vaccinia virus which has an excellent 
safety record, as it was used in the final stages of the smallpox eradication. MVA 
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expressing a major secreted antigens from M. tuberculosis, antigen 85A, was the first new 
tuberculosis vaccine to enter into clinical trials in September 2002. This vaccine is known 
as MVA85A. In a series of phase I clinical trials in the United Kingdom, MVA85A had an 
excellent safety profile and was highly immunogenic (Ibanga et al., 2006). MVA85A is a 
new-generation vaccine against TB which produced higher levels of long-lasting cellular 
immunity as it used as a booster in BCG priming (McShane et al., 2004) 
 
1.3.4            Mycobacterial epitopes as an antigen and its potential 
 
The genome of M. tuberculosis has been sequenced earlier (Cole et al., 1998). The 
availability of the genome sequence has enabled further characteristics of the 
mycobacterial protein to identify the suitable gene that can stimulate immune response 
against TB. A number of immunodominant antigens (e.g ESAT-6, Ag85B and Mtb8.4) are 
recognized by infected subject from different ethnic background. Both CD4+ and CD8+ T 
cell epitopes have been identified on these proteins and may be used to evaluate host 
response to the vaccine incorporating the antigens (Britton & Palendira, 2003).  
 
1.3.4.1       6 kDa Early Secretory antigenic target  (ESAT-6) 
 
ESAT-6 is a low mass culture filtrate with highly immunoreactive properties (Brandt et al., 
1996; Andersen, 2001). The major T-cell epitope on this molecule is recognized by a high 
frequency of T-cell during the recall of immunity to TB. The ESAT-6 gene is present in M. 
tuberculosis and virulent M. bovis but not in M. bovis BCG vaccine strain (Harboe et al., 
1996; Behr et al., 1999; Bao et al., 2003). ESAT-6 antigen is considered to play a 
protective role as a target of protective immune response (Kamath et al., 1999; Brandt et 
al., 2000, Andersen, 2001). 
 19
1.3.4.2      Antigen 85 complex 
 
The proteins of the antigen 85 (Ag85) complexes are the major secretion product of M. 
tuberculosis and M. bovis (Wiker & Harboe, 1992). The Ag85 complex (A, B and C) 
consists of a family of 30-32 kDa protein that acts as mycocyl transferases (Belisle et al., 
1997). Ag85 complex induces strong T-cell proliferation and IFN-γ production in most 
healthy individuals infected with M. tuberculosis or M. leprae and in BCG-vaccinated mice 
and human. Tanghe et al. (2000) had demonstrated that vaccination with plasmid DNA 
encoding Ag85A resulted in a strong humoral and cellular immune response and gave 
important protection in C57BL/6 mice challenged by aerosol with live M. tuberculosis 
H37Rv. The three immunodominant epitopes of the 30, 32 and 16 kDa major extracellular 
proteins of M. tuberculosis had been identified by Lee & Horwitz in 1999. Proliferative 
response assays from outbred guinea pig which was immunized with each of the three 
proteins showed that 30 kDa (known as Ag85B) is the most immunogenic of the three 
proteins tested. 
 
1.3.4.3       Mtb8.4 
 
Mtb8.4 is a low molecular weight of M. tuberculosis culture filtrate protein (estimated 
molecular weight was 8.4 kDa) which is an immunodominant T cell antigen. 
Immunogenecity study in mice has demonstrated that Mtb8.4 elicits Th1 cytokines profile, 
which leads to IFN-γ production which is important for protective immunity against TB. In 
addition, Mtb8.4 was reported to elicit proliferation and production of IFN-γ from human 
peripheral blood mononuclear cell (PBMC) of PPD+ healthy individuals (Coler et al., 1998, 
Coler et al., 2001). 
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1.4               Aim of the study 
 
As described previously, BCG is the only vaccine available against TB, which is routinely 
practiced in many countries. However, due to the differentiation and limitation of BCG 
vaccination, there is an urgent need for another potential vaccine candidate. Therefore, we 
aimed to construct a new multi-epitopes synthetic DNA vaccine candidate expressing the 
most promising mycobacterial antigens of M. tuberculosis as an alternative vaccine against 
TB. The specific objective of this study as follows: 
 
1. To synthesis a multi synthetic gene (VacIV) of M. tuberculosis 
2. To study the expression of the cloned gene (VacIV) 
3. To construct a DNA vaccine candidate (pVaxVacIV). 
4. To determine the immunogenicity of DNA vaccine candidate in C57BL/6 mice 
 
Firstly, we aim to synthesis a VacIV gene encoding Mtb8.4, Ag85A (32 kDa) and Ag85B 
(30 kDa) gene of M. tuberculosis by assembly polymerase chain reaction (PCR).  Then, 
the gene will be cloned into pCR®2.1 TOPO cloning vector to construct a recombinant 
plasmid namely pTOPOVacIV for DNA sequencing analysis, restriction enzyme analysis 
and screening by PCR.  As we get the positive clone, the VacIV gene will be removed from 
pTOPOVacIV and cloned into pVAX1© eukaryotic expression vector to produce a DNA 
vaccine candidate namely pVaxVacIV. In addition, the VacIV gene will be cloned into 
pPROEXTM HTb prokaryotic expression vector for expression study in E. coli and further 
purified of recombinant VacIV protein. The DNA vaccine candidate will be tested in 
C57BL/6 mice for immunogenicity study which involved measurement of IFN-γ and IL-4 
cytokines, lymphocytes proliferation assay and determination of IgG subclasses. The 
flowchart of the overall study is illustrated in Figure 1.2. 
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Synthesis of VacIV gene encoding Mtb8.4, Ag85A 
(32 kDa) and Ag85B (30 kDa) gene of M. 
tuberculosis by assembly PCR 
Cloning VacIV gene in pCR®2.1 TOPO® vector 
Screening of clones by restriction enzyme (RE) 
digestion, PCR and DNA sequencing. 
RE digestion by HindIII-EcoRI 
to remove VacIV gene 
RE digestion by SacI-XbaI to 
remove VacIV gene 
RE digestion of pVAX1© with 
HindIII-EcoRI 
RE digestion of pPROEXTM 
HTb with SacI-XbaI 
-HindIII-VacIV-EcoRI- -SacI-VacIV-XbaI- 
pROVacIV pVaxVacIV 
Immunogenecity of pVaxVacIV in 
C57 BL/6 mice by intramuscular 
immunization. 
Splenocytes preparation 
Expression  study and purification 
of recombinant VacIV protein 
Sera collection 
Lymphocytes proliferation 
assay 
Measurement of IFN-γ and 
IL-4 cytokines by ELISA 
Determination of IgG1 
and IgG2a subclasses 
Ligation Ligation 
Figure 1.2: The flowchart of the overall of this study 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1  MATERIALS 
 
2.1.1  Mice  
 
Female mice strain C57BL/6 at 6-8 week-old were used in this study were obtained from 
Animal House of USM Health Campus, Kelantan. Animal care and experimentation 
procedures have been approved by the Animal Ethics Committee, USM. 
 
2.1.2             Bacterial strains 
 
Two different strains of Escherichia coli (E. coli) which are TOP 10 and DH5α from 
Invitrogen (USA) were used in this study. The bacterial cells were grown in Luria-bertani 
(LB) broth and LB-agar. The bacteria were stored in glycerol stock at –80oC.  
 
2.1.3  Oligonucleotides and primers 
 
Thirty five overlapping nucleotides and primers for assembly PCR used in this study were 
manufactured by MWG (Germany) which purchased through Research Instruments Sdn. 
Bhd. Malaysia. All oligonucleotides and primers were resuspended overnight at 4oC by 
adding an appropriate amount of distilled deionized water to make a stock of 250 μM. The 
primers were diluted to make a 10 μM of working stock solution. All oligonucleotides and 
primers were stored at –20oC. 
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2.1.4  Plasmids 
 
The plasmids used in this study were pCR®2.1 TOPO cloning vector (Figure 2.1a), 
pVAX1© eukaryotic expression vector (Figure 2.1b) and pPROEXTMHTb prokaryotic 
expression vector (Figure 2.1c). All plasmids were purchased from Invitrogen (USA). 
 
2.1.5            Chemicals and reagents 
 
All chemicals, reagents and enzymes (restriction enzymes, DNA polymerase and DNA 
ligase) used in this study are listed in Table 2.1. 
 
2.1.6            Kits and laboratory equipments 
 
All kits and equipment used in this study are listed in Table 2.2 and 2.3. 
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Figure 2.1a: The map of pCR®2.1 TOPO® cloning vector (adapted from 
http://www.invitrogen.com/content/sfs/vector/pcr2_1topo_map.pdf.) 
 
 
 
 
